<DOC>
	<DOCNO>NCT00002549</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy follow bone marrow peripheral stem cell transplantation treat patient acute myelogenous leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Acute Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine complete remission ( CR ) rate follow 1 2 course ICE ( idarubicin/cytarabine/etoposide ) vs. MICE ( mitoxantrone/cytarabine/etoposide ) vs. DCE ( daunorubicin/cytarabine/etoposide ) patient newly diagnose acute myeloid leukemia . II . Compare disease-free survival overall survival achieve anthracycline induction regimens intermediate-dose cytarabine ( IDIA vs. NOVIA vs. DIA ) consolidation therapy . III . Compare disease-free survival , relapse rate , death first CR , overall survival patient receive peripheral blood stem cell ( PBSC ) vs. autologous bone marrow transplant ( AuBMT ) vs. allogeneic bone marrow transplant ( AlBMT ) rescue myeloablative therapy follow remission consolidation . IV . Assess time recovery normal acceptable polymorphonuclear leukocyte platelet count follow treatment step . V. Determine incidence type grade 4 toxicity treatment-related mortality . VI . Evaluate quality life step treatment use self-administered questionnaire . VII . Compare stem cell mobilization IDIA vs. NOVIA vs. DIA , use granulocyte colony-stimulating factor mobilize growth factor . VIII . Assess rate completion stem cell transplantation use PBSC vs. AlBMT vs. AuBMT last step therapy . IX . Compare cost treatment ( e.g. , antibiotic transfusion requirement ) hospitalization duration AuBMT vs. PBSC . OUTLINE : Randomized study . All patient randomize Arms I , II , III Induction/Consolidation . Patients CR follow Consolidation HLA-identical sibling , less 45 55 year age ( depend center policy ) , adequate organ function nonrandomly assign AlBMT Regimen A ; CR without available sibling donor adequate organ function proceed Regimen B , randomize Arms IV V. The following acronym use : AlBMT Allogeneic Bone Marrow Transplant ARA-C Cytarabine , NSC-63878 AuBMT Autologous Bone Marrow Transplant BU Busulfan , NSC-750 CTX Cyclophosphamide , NSC-26271 DCE DNR/ARA-C/VP-16 DHAD Mitoxantrone , NSC-301739 DIA DNR/ID ARA-C DNR Daunorubicin , NSC-82151 G-CSF Granulocyte Colony-Stimulating Factor ( Rhone-Poulenc-Rorer ) ICE IDA/ARA-C/VP-16 IDA Idarubicin , NSC-256439 ID Intermediate Dose IDIA IDA/ID ARA-C Mesna Mercaptoethane sulfonate , NSC-113891 MICE DHAD/ARA-C/VP-16 NOVIA DHAD/ID ARA-C PBSC Peripheral Blood Stem Cells TBI Total-Body Irradiation VP-16 Etoposide , NSC-141540 INDUCTION/CONSOLIDATION : Arm I : 3-Drug Combination Chemotherapy follow 2-Drug Combination Chemotherapy . ICE ; follow IDIA . Arm II : 3-Drug Combination Chemotherapy follow 2-Drug Combination Chemotherapy . MICE ; follow NOVIA . Arm III : 3-Drug Combination Chemotherapy follow 2-Drug Combination Chemotherapy . DCE ; follow DIA . POSTCONSOLIDATION THERAPY : Regimen A : Single-Agent Chemoablation plus Radioablation 2-Drug Chemoablation follow Hematopoietic Rescue . CTX ; plus TBI ( equipment unspecified ) ; CTX/BU ; follow AlBMT . Entry EORTC study compare CI IDA standard CTX/TBI CTX/BU encourage . Regimen B : Stem cell Mobilization Harvest . G-CSF CTX/G-CSF . Arm IV : Single-Agent Chemoablation plus Radioablation 2-Drug Chemoablation follow Hematopoietic Rescue . CTX/TBI CTX/BU ; follow PBSC . Arm V : Single-Agent Chemoablation plus Radioablation 2-Drug Chemoablation follow Hematopoietic Rescue . CTX/TBI CTX/BU ; follow AuBMT . PROJECTED ACCRUAL : 1,520 patient randomize Induction/Consolidation 5 year ; excessive death find interim analysis , inferior arm close . It expect 744 patient randomized Postconsolidation therapy , 345 patient follow relapse/death .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute myeloid leukemia ( AML ) FAB histology ( M1M7 ) except M3 At least 30 % blast cell bone marrow smear Secondary leukemia eligible , follow : Following cured malignancy , include Hodgkin 's disease Following exposure alkylating agent radiotherapy reason The follow leukemia exclude : Blast crisis chronic myeloid leukemia Leukemia secondary myeloproliferative disease Leukemia secondary myelodysplastic syndrome 6 month ' duration No progressive malignant disease PATIENT CHARACTERISTICS : Age : 15 60 Performance status : Not specify Hematopoietic : Not applicable Hepatic : Bilirubin great 1.5 x ULN Renal : Creatinine great 1.5 x ULN Cardiovascular : No severe heart failure require diuretic LVEF le 50 % Other : No severe concomitant neurologic disease No severe concomitant psychologic disease PRIOR CONCURRENT THERAPY : No prior therapy AML ( chemotherapy , radiotherapy , 7 day corticosteroid )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
</DOC>